[go: up one dir, main page]

MXPA02012244A - 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal. - Google Patents

1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal.

Info

Publication number
MXPA02012244A
MXPA02012244A MXPA02012244A MXPA02012244A MXPA02012244A MX PA02012244 A MXPA02012244 A MX PA02012244A MX PA02012244 A MXPA02012244 A MX PA02012244A MX PA02012244 A MXPA02012244 A MX PA02012244A MX PA02012244 A MXPA02012244 A MX PA02012244A
Authority
MX
Mexico
Prior art keywords
nicotinic receptor
alkylcyclohexanes
amino
aminoalkylcyclohexanes
serotoninergic
Prior art date
Application number
MXPA02012244A
Other languages
English (en)
Inventor
Aigars Jirgensons
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MXPA02012244A publication Critical patent/MXPA02012244A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Algunos 1-aminoalquilciclohexanos son antagonistas de los receptores 5-HT3 y nicotinicos, activos de manera sistemica, son utiles en la inhibicion o progreso o en el alivio de condiciones que resultan de alteraciones de la transmision serotoninergica o nicotinergica lo que les proporciona una amplia gama de utilidad en el tratamiento de desordenes del SNC. Se proporcionan composiciones farmaceuticas de los mismos para tal proposito e igualmente se describen metodos para su elaboracion asi como un metodo para tratar condiciones que se alivian mediante la utilizacion del antagonista receptor de 5HT3 o neuronal nicotinico.
MXPA02012244A 2000-06-20 2001-06-19 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal. MXPA02012244A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59710200A 2000-06-20 2000-06-20
PCT/EP2001/006964 WO2001098253A2 (en) 2000-06-20 2001-06-19 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists

Publications (1)

Publication Number Publication Date
MXPA02012244A true MXPA02012244A (es) 2004-09-06

Family

ID=24390098

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012244A MXPA02012244A (es) 2000-06-20 2001-06-19 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal.

Country Status (20)

Country Link
US (2) US20070105961A1 (es)
EP (2) EP2277850A1 (es)
JP (1) JP4159351B2 (es)
KR (1) KR100570374B1 (es)
CN (1) CN1307147C (es)
AR (1) AR032756A1 (es)
AU (2) AU2001281861B2 (es)
CA (1) CA2410852C (es)
CZ (1) CZ2003497A3 (es)
EA (1) EA006067B1 (es)
GE (1) GEP20053431B (es)
HU (1) HUP0301551A3 (es)
IL (2) IL153480A0 (es)
MX (1) MXPA02012244A (es)
NO (1) NO329491B1 (es)
PL (1) PL359583A1 (es)
TW (1) TW593223B (es)
UA (1) UA74194C2 (es)
WO (1) WO2001098253A2 (es)
ZA (1) ZA200104187B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
WO2004037234A2 (en) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
KR20070104480A (ko) 2003-05-27 2007-10-25 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 ｎｍｄａ수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
US20070082956A1 (en) * 2003-07-28 2007-04-12 Merz Pharma Gmbh & Co. Kgaa The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity.
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP2397122B1 (en) * 2004-06-17 2014-05-14 Merz Pharma GmbH & Co. KGaA Formulations of neramexane dosage forms
WO2006078239A1 (en) 2005-01-18 2006-07-27 University Of Florida Compositions and methods for inhibiting pain
ES2673016T3 (es) 2008-11-19 2018-06-19 Forum Pharmaceuticals Inc. Tratamiento de los síntomas negativos de la esquizofrenia con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma
US8399519B2 (en) 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
EP3604302A1 (en) 2010-05-17 2020-02-05 Forum Pharmaceuticals Inc. Preparation of crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
US5886051A (en) * 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
DK1009732T3 (da) 1997-06-30 2003-09-22 Merz Pharma Gmbh & Co Kgaa 1-Amino-alkylcyclohexan NMDA receptor antagonister
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Also Published As

Publication number Publication date
EA006067B1 (ru) 2005-08-25
WO2001098253A2 (en) 2001-12-27
CA2410852C (en) 2007-04-24
NO20026103L (no) 2003-02-19
EA200300040A1 (ru) 2003-06-26
HUP0301551A2 (hu) 2003-11-28
CZ2003497A3 (cs) 2004-08-18
CN1620419A (zh) 2005-05-25
ZA200104187B (en) 2002-11-22
IL153480A (en) 2007-08-19
AU8186101A (en) 2002-01-02
KR20030053475A (ko) 2003-06-28
US20100298442A1 (en) 2010-11-25
HK1076276A1 (en) 2006-01-13
HUP0301551A3 (en) 2005-04-28
WO2001098253A3 (en) 2002-04-25
JP2004501130A (ja) 2004-01-15
GEP20053431B (en) 2005-01-25
TW593223B (en) 2004-06-21
CN1307147C (zh) 2007-03-28
JP4159351B2 (ja) 2008-10-01
AR032756A1 (es) 2003-11-26
PL359583A1 (en) 2004-08-23
KR100570374B1 (ko) 2006-04-24
AU2001281861B2 (en) 2006-08-17
US20070105961A1 (en) 2007-05-10
NO20026103D0 (no) 2002-12-19
CA2410852A1 (en) 2001-12-27
UA74194C2 (uk) 2005-11-15
EP1303477A2 (en) 2003-04-23
EP2277850A1 (en) 2011-01-26
NO329491B1 (no) 2010-10-25
IL153480A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
MXPA02012244A (es) 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal.
MXPA05002442A (es) Imidazolopiridinas y metodos para la elaboracion y uso de las mismas.
WO1999001416A3 (en) 1-amino-alkylcyclohexane nmda receptor antagonists
MXPA05008524A (es) Pirazoles y metodos de elaboracion y uso de los mismos.
AU2003259747A8 (en) Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2004020599A3 (en) Hedgehog antagonists, methods and uses related thereto
IL114599A (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containg them
UA81624C2 (ru) Тризамещённые гетероарилы и способ их получения и применение
BG108683A (en) Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
WO2002030462A3 (en) Hedgehog antagonists, methods and uses related thereto
WO1999048523A3 (en) Antagonists of the inflammatory mediator oncostatin m (osm)
WO2003028641A3 (en) Mch receptor antagonists
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
NO20060719L (no) Substituerte cykloalkylaminderivater som modulatorer av kemokin reseptor aktivitet
WO2004091514A3 (en) Cgrp receptor antagonists
GEP20074125B (en) Pyrazolopyridines and methods of making and using the same
AU2003228674A1 (en) Muscarinic antagonists
PL343467A1 (en) Heterocyclically substituted amides, their production and their use
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
DE69908173D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
NO20004502D0 (no) Nye sammensetninger av eprosartan

Legal Events

Date Code Title Description
FG Grant or registration